120 related articles for article (PubMed ID: 36747791)
1. Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction.
Selli ME; Landmann JH; Terekhova M; Lattin J; Heard A; Hsu YS; Chang TC; Chang J; Warrington J; Ha H; Kingston N; Hogg G; Slade M; Berrien-Elliot MM; Foster M; Kersting-Schadek S; Gruszczynska A; DeNardo D; Fehniger TA; Artyomov M; Singh N
bioRxiv; 2023 Jan; ():. PubMed ID: 36747791
[TBL] [Abstract][Full Text] [Related]
2. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction.
Selli ME; Landmann JH; Terekhova M; Lattin J; Heard A; Hsu YS; Chang TC; Chang J; Warrington J; Ha H; Kingston N; Hogg G; Slade M; Berrien-Elliott MM; Foster M; Kersting-Schadek S; Gruszczynska A; DeNardo D; Fehniger TA; Artyomov M; Singh N
Blood; 2023 Jun; 141(26):3153-3165. PubMed ID: 37130030
[TBL] [Abstract][Full Text] [Related]
3. CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells.
Mezősi-Csaplár M; Szöőr Á; Vereb G
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370693
[TBL] [Abstract][Full Text] [Related]
4. Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells.
Nguyen P; Okeke E; Clay M; Haydar D; Justice J; O'Reilly C; Pruett-Miller S; Papizan J; Moore J; Zhou S; Throm R; Krenciute G; Gottschalk S; DeRenzo C
Mol Ther Oncolytics; 2020 Sep; 18():202-214. PubMed ID: 32728609
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
Hu W; Huang X; Huang X; Chen W; Hao L; Chen Z
Biomed Pharmacother; 2019 Oct; 118():109333. PubMed ID: 31545280
[TBL] [Abstract][Full Text] [Related]
6. MyD88/CD40 signaling retains CAR T cells in a less differentiated state.
Prinzing B; Schreiner P; Bell M; Fan Y; Krenciute G; Gottschalk S
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 33148882
[TBL] [Abstract][Full Text] [Related]
7. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells.
Tan J; Jia Y; Zhou M; Fu C; Tuhin IJ; Ye J; Monty MA; Xu N; Kang L; Li M; Shao J; Fang X; Zhu H; Yan L; Qu C; Xue S; Jin Z; Chen S; Huang H; Xu Y; Chen J; Miao M; Tang X; Li C; Yan Z; Wu D; Yu L
J Hematol Oncol; 2022 Apr; 15(1):39. PubMed ID: 35365211
[TBL] [Abstract][Full Text] [Related]
9. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
10. Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.
Yi Z; Prinzing BL; Cao F; Gottschalk S; Krenciute G
Mol Ther Methods Clin Dev; 2018 Jun; 9():70-80. PubMed ID: 29552579
[TBL] [Abstract][Full Text] [Related]
11. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
12. An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment.
Khuisangeam N; Jewmoung S; Thaiwong R; Tudsamran S; Hirankarn N; Suppipat K; Tawinwung S
J Immunol Res; 2022; 2022():2449373. PubMed ID: 36457849
[TBL] [Abstract][Full Text] [Related]
13. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
14. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain.
Liang X; Huang Y; Li D; Yang X; Jiang L; Zhou W; Su J; Chen N; Wang W
Gene Ther; 2023 May; 30(5):411-420. PubMed ID: 33953316
[TBL] [Abstract][Full Text] [Related]
15. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
Boroughs AC; Larson RC; Marjanovic ND; Gosik K; Castano AP; Porter CBM; Lorrey SJ; Ashenberg O; Jerby L; Hofree M; Smith-Rosario G; Morris R; Gould J; Riley LS; Berger TR; Riesenfeld SJ; Rozenblatt-Rosen O; Choi BD; Regev A; Maus MV
Mol Ther; 2020 Dec; 28(12):2577-2592. PubMed ID: 32755564
[TBL] [Abstract][Full Text] [Related]
16. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
[TBL] [Abstract][Full Text] [Related]
17. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
[TBL] [Abstract][Full Text] [Related]
19. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
